

- 3. Report of NANPA Oversight Working Group
  - Proposed Process to Resolve PIPs
  - Status of NANPA Requirements Document
  - Status of NANPA Performance Review
- 4. Report of Numbering Resource Optimization (NRO) Working Group
  - Final NRUF Requirements
  - Continuing Review of NANP-Exhaust
  - Monitoring of State Pooling Trials
- 5. Industry Numbering Committee Report
- 6. Report of Toll Free Access Codes IMG
- 7. Report of the Local Number Portability Administration (LNPA) Working Group
  - Wireless Number Portability Subcommittee
- 8. Report of Cost Recovery Working Group
  - Status of NBANC B&C Technical Requirements
- 9. Report from NBANC
- 10. Reseller CIC IMG status report
- 11. Oversight of LLCs NPAC
- 12. Meeting Procedures IMG
- 13. Action Items
- 14. Steering Group Meeting
  - Table of NANC Projects
  - Change September 18–19 Meeting to September 11–12
- 15. The Big Picture Discussion
- 16. Public Participation (5 minutes each, if any)
- 17. Other Business

Federal Communications Commission.

**Diane Griffin Harmon,**

*Deputy Chief, Network Services Division, Common Carrier Bureau.*

[FR Doc. 01–2948 Filed 2–2–01; 8:45 am]

**BILLING CODE 6712–01–P**

## FEDERAL RESERVE SYSTEM

### Sunshine Act Meeting

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System.

**TIME AND DATE:** 2:00 p.m., Thursday, February 8, 2001.

**PLACE:** Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

**STATUS:** Closed

**MATTERS TO BE CONSIDERED:**

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

**CONTACT PERSON FOR MORE INFORMATION:**

Lynn S. Fox, Assistant to the Board; 202–452–3204.

**SUPPLEMENTARY INFORMATION:** You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: February 1, 2001.

**Robert deV. Frierson,**

*Associate Secretary of the Board.*

[FR Doc. 01–3052 Filed 2–1–01; 11:40 am]

**BILLING CODE 6210–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Care Financing Administration [HCFA–3061–N]

#### Medicare Program; Meetings of the Medical Devices and Prosthetics Panel and the Executive Committee of the Medicare Coverage Advisory Committee; February 21 and 22, 2001

**AGENCY:** Health Care Financing Administration (HCFA), HHS.

**ACTION:** Notice of meetings.

**SUMMARY:** This notice announces public meetings of the Medical Devices and Prosthetics Panel (the Panel) and the Executive Committee (EC) of the Medicare Coverage Advisory Committee (MCAC). The Panel and the EC will provide advice and recommendations to HCFA about clinical issues.

On Wednesday, February 21, 2001, the Panel will hear and discuss presentations from interested persons regarding ambulatory blood pressure monitoring for the diagnosis and treatment of hypertension. On Thursday, February 22, 2001, the meeting of the EC will be to discuss comments received on the March 1, 2000, interim recommendations for evaluating effectiveness of the MCAC process. It will also ratify or comment on the recommendations of the Medical and Surgical Procedures Panel meeting that took place on October 17 and 18, 2000 regarding both electrostimulation for the treatment of chronic wounds and sacral nerve stimulation for the treatment of incontinence.

Notice of these meetings is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)).

**DATES:** *The Meetings:* The meetings will be held on Wednesday, February 21,

and Thursday, February 22, 2001, respectively, from 8 a.m. until 4 p.m., E.S.T.

*Deadline for Presentation Notification and Comments:* February 14, 2001, 5 p.m., E.S.T.

*Special Accommodations:* Persons attending the meetings who are hearing- or visually-impaired, and/or have a condition that requires special assistance/accommodations, are asked to notify the respective Executive Secretaries by February 14, 2001.

**ADDRESSES:** *The Meetings:* The meetings will be held at the Baltimore Convention Center, Rooms 327 and 328 (for both days), One West Pratt Street, Baltimore, MD 21201.

*Presentations and Comments:* Submit formal presentations and written comments for the Panel's discussion on ambulatory blood pressure monitoring for the diagnosis and treatment of hypertension to Patricia M. Brocato-Simons, Executive Secretary, Office of Clinical Standards and Quality, Health Care Financing Administration, 7500 Security Boulevard, Mail Stop S3–02–01, Baltimore, MD 21244–1850.

Submit formal presentations and written comments for the EC's discussions on interim recommendations for evaluating effectiveness of the MCAC process, or on electrostimulation for the treatment of chronic wounds and sacral nerve stimulation for the treatment of incontinence to Constance A. Conrad, Executive Secretary, Office of Clinical Standards and Quality, Health Care Financing Administration, 7500 Security Boulevard, Mail Stop S3–02–01, Baltimore, MD 21244–1850.

*Website:* You may access up-to-date information on this meeting at [www.hcfa.gov/quality/8b.htm](http://www.hcfa.gov/quality/8b.htm).

*Hotline:* You may access up-to-date information on this meeting on the HCFA Advisory Committee Information Hotline, 1–877–449–5659 (toll free) or in the Baltimore area (410) 786–9379.

**FOR FURTHER INFORMATION CONTACT:** Patricia M. Brocato-Simons, Executive Secretary for the Panel, at 410–786–0261, or Constance A. Conrad, Executive Secretary for the EC, at 410–786–4631.

**SUPPLEMENTARY INFORMATION:** On August 13, 1999, we published a notice (64 FR 44231) to describe the Medicare Coverage Advisory Committee (MCAC), which provides advice and recommendations to us about clinical issues. This notice announces the

following public meetings of the Medical Devices and Prosthetics Panel (the Panel) and the Executive Committee (EC) of the MCAC:

#### The Medical Devices and Prosthetics Panel and Invited Guests

Harold Sox, Jr., M.D.; Ronald Davis, M.D.; Willarda Edwards, M.D.; John Hinton, D.O., M.P.H.; Anne Roberts, M.D.; Karl Matuszewski, M.S., PharmD; Thomas Strax, M.D.; Wade Aubry, M.D.; Rory Cooper, Ph.D.; and Eileen Helzner, M.D. In addition, two invitees will attend the Panel meeting and lend their respective expertise to the deliberations: Kenneth Brin, M.D., M.P.H, a current member of the Medical and Surgical Procedures Panel, with a specialty in the field of cardiology, will serve as a temporary, voting member of the Panel; and Parker Staples, M.D., the Carrier Medical Director for the State of Rhode Island, will serve as a temporary, non-voting guest of the Panel.

#### Topic of the Meeting

On Wednesday, February 21, 2001, the Panel will hear and discuss presentations from interested persons regarding ambulatory blood pressure monitoring for the diagnosis and treatment of hypertension.

#### The EC Members:

Alan M. Garber, M.D.; Michael D. Maves, M.D.; Daisy Alford-Smith, M.D.; Joe Johnson, D.C.; Harold Sox, M.D.; Ronald Davis, M.D.; Frank Papatheofanis, M.D., Ph.D.; John Ferguson, M.D.; Robert Murray, J.D., Ph.D.; Thomas Holohan, M.D., M.B.A.; Leslie Francis, Ph.D., J.D.; Robert Brook, M.D., Linda Berghthold; and Randel Richner, M.P.H.

#### Topic of the Meeting

On Thursday, February 22, 2001, the EC will hear and discuss presentations from interested persons regarding comments received on interim recommendations for evaluating effectiveness of the MCAC process. The guidelines were developed on March 1, 2000, for the purpose of providing guidance to the specialty panels. It will also ratify or comment on recommendations regarding electrostimulation for the treatment of chronic wounds and sacral nerve stimulation, discussed by the Medical and Surgical Procedures Panel on October 17 and 18, 2000.

#### Procedure and Agenda

The meetings are open to the public. Oral presentations will be heard from the public for approximately 2.5 hours each meeting day. However, the number

and duration of each oral presentation may be limited in recognition of the time available. If you wish to make formal presentations, you must notify the respective Executive Secretaries listed in the **FOR FURTHER INFORMATION CONTACT** section of this notice, and submit the following by the Deadline for Presentations and Comments date listed in the **DATES** section of this notice: a brief statement of the general nature of the evidence or arguments you wish to present, the names and addresses of proposed participants, and an estimate of the time required to make the presentation. A written copy of your presentation will be provided to each Panel or EC member prior to offering your public comments. We will request that you declare at the meetings whether or not you have any financial involvement with manufacturers of any items or services being discussed (or with their respective competitors).

After HCFA presentations, the public will be asked to make its presentations to the Panel (February 21) or the EC (February 22). After public presentations, the Panel or the EC will deliberate openly on the topic. Interested persons may observe the deliberations, but the Panel or the EC will not hear further comments during this time except at the request of the chairpersons. Each day, there will be approximately a 30-minute open public session for any attendee to address issues specific to the topic. At the conclusion of each day, the respective members will vote, and the Panel or the EC will make its recommendations.

**Authority:** 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: January 26, 2001.

**Jeffrey L. Kang,**

*Director, Office of Clinical Standards and Quality, Health Care, Financing Administration*

[FR Doc. 01-2941 Filed 2-2-01; 8:45 am]

**BILLING CODE 4120-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This Notice is also available on the internet at the following website: <http://www.health.org/workplace>

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014, Fax: (301) 443-3031.

**Special Note:** Please use the above address for all surface mail and correspondence. For all overnight mail service use the following address: Division of Workplace Programs, 5515 Security Lane, Room 815, Rockville, Maryland 20852.

**SUPPLEMENTARY INFORMATION:** Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.